Cannabinoid Treatment Significantly Reduces Fibromyalgia Pain And Improves Quality Of Life, New Tilray-Backed Study Finds
Tilray Medical, a division of Canadian cannabis giant Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Monday a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS).
The study, consisting of patients with an average age of 52 years, examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers.
More precisely, the researchers take a closer look at the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study examined the impact of cannabinoids on health outcomes, with a focus on pain, sleep, and quality of life.
Read Also: Billion-Dollar Cannabis Company Closes Acquisition …